---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-25-000005"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2025-01-15T23:59:59+00:00"
generated_at: "2026-05-28T01:14:25.521020+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amneal expects to meet or exceed 2024 full-year guidance; net leverage ~4x

## Summary
- Expects to meet net revenue ($2.70-2.80B), adjusted EBITDA ($610-630M), and adjusted diluted EPS ($0.57-0.63).
- Expects to exceed operating cash flow guidance ($280-320M) and capital expenditure guidance ($60-70M).
- Estimates net leverage at approximately 4x as of December 31, 2024.
- Guidance includes 100% of AvKARE EBITDA; adjusted EPS accounts for 35% non-controlling interest.

## SEC filing metadata
- accession: 0001723128-25-000005
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2025-01-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000005/0001723128-25-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000005/amrx-20250115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-25-000005
- JSON: https://secwatch.observer/filing/0001723128-25-000005.json
- Plain text: https://secwatch.observer/filing/0001723128-25-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.